Gastrin I (human): Precision Modeling of CCK2 Signaling in Intestinal Organoids

Introduction

Understanding the intricate regulation of gastric acid secretion is central to gastrointestinal (GI) physiology and the pathogenesis of GI disorders. Gastrin I (human), a potent endogenous regulatory peptide, stands at the forefront of modern research as a highly specific tool for probing the gastric acid secretion pathway and receptor-mediated signal transduction. While previous literature has highlighted the utility of Gastrin I (human) in organoid and cell-based models (as discussed here), this article offers a distinct, in-depth exploration: we focus on integrating Gastrin I (human) into advanced human pluripotent stem cell-derived intestinal organoid systems, leveraging the latest breakthroughs in organoid technology to precisely dissect CCK2 receptor signaling, proton pump activation, and their implications for translational medicine.

The Role of Gastrin I (human) in Gastric Acid Secretion Regulation

Biochemical Identity and Receptor Specificity

Gastrin I (human) is a 17-amino acid peptide (CAS: 10047-33-3; MW: 2098.22 Da) produced endogenously by G cells of the stomach antrum. Its primary biological function is to stimulate gastric acid secretion by binding with high affinity to the cholecystokinin B receptor (CCK2 receptor) on gastric parietal cells. Acting as a CCK2 receptor agonist, Gastrin I triggers intracellular signaling cascades that culminate in the activation of the gastric H⁺/K⁺-ATPase (proton pump), driving acidification of the gastric lumen.

Mechanistic Insights: Signal Transduction and Proton Pump Activation

Upon receptor engagement, Gastrin I (human) activates the phospholipase C (PLC) pathway, leading to inositol triphosphate (IP3) generation, intracellular calcium mobilization, and subsequent stimulation of the proton pump. This receptor-mediated signal transduction is not only pivotal for physiological acid secretion but is also a key node in the pathophysiology of hypergastrinemia-associated disorders, such as Zollinger-Ellison syndrome and certain gastric cancers.

State-of-the-Art: Human Intestinal Organoids as a Model System

Limitations of Traditional Models in Gastric Acid Secretion Pathway Research

Conventional in vitro models, such as Caco-2 cells and animal-derived tissues, have advanced our understanding but are limited by species-specific differences and poor recapitulation of human gastric physiology. Notably, Caco-2 cells, while widely used, underexpress critical drug-metabolizing enzymes, limiting their relevance for pharmacokinetic and mechanistic studies (Takumi Saito et al., 2025).

Breakthroughs in Organoid Technology

Recent advances have enabled the generation of human induced pluripotent stem cell (hiPSC)-derived intestinal organoids. These three-dimensional (3D) models faithfully reproduce the cellular diversity, architecture, and functional properties of the native intestinal epithelium, including absorptive enterocytes, secretory goblet cells, enteroendocrine cells, and Paneth cells. The work by Saito et al. (2025) established robust protocols for deriving self-renewing, cryopreservable IOs with mature IECs exhibiting physiologically relevant transporter and cytochrome P450 enzyme activity. This paradigm shift provides a powerful and physiologically relevant platform for gastrointestinal physiology studies and drug discovery.

Integrating Gastrin I (human) into Advanced Organoid Workflows

Experimental Design: Leveraging Gastrin I in hiPSC-Derived Organoids

By introducing Gastrin I (human) into hiPSC-derived intestinal organoid cultures, researchers can:

• Precisely activate the CCK2 receptor signaling pathway, enabling controlled studies of downstream effects on acid secretion and epithelial function.
• Model pathological states by modulating Gastrin I concentration to mimic hypergastrinemic or hypoacidic conditions.
• Investigate the cross-talk between proton pump activation, epithelial homeostasis, and drug metabolism in a human-relevant context.

Technical Considerations: Handling and Solubility

Gastrin I (human) is supplied as a white lyophilized solid of high purity (≥98%, HPLC and MS verified), insoluble in water and ethanol but readily soluble in DMSO (≥21 mg/mL). For optimal stability and reproducibility in organoid experiments, the peptide should be stored desiccated at −20°C, and solutions prepared fresh shortly before use. This ensures maximal bioactivity and minimizes batch variability, critical for rigorous gastric acid secretion pathway research.

Comparative Analysis: Gastrin I (human) vs. Alternative Approaches

Benchmarking Against Animal Models and Alternative Agonists

While animal models and alternative synthetic agonists have been used to study gastric acid secretion, they often lack the receptor specificity or human physiological relevance provided by Gastrin I (human) in hiPSC-derived systems. The use of human Gastrin I peptide in organoid models enables:

• Direct interrogation of human-specific CCK2 receptor signaling.
• Quantitative assessment of proton pump activation in a system that mirrors the in vivo human gastric environment.
• Integration with pharmacokinetic studies, as demonstrated in the context of drug metabolism using organoid models (Saito et al., 2025).

Content Differentiation: Beyond Existing Literature

Previous articles, such as "Gastrin I (human): A Versatile Tool for Gastric Acid Secretion", have focused on the peptide’s application in dissecting proton pump activation and receptor-mediated pathways within conventional in vitro models. Our current article advances the discussion by situating Gastrin I (human) at the nexus of next-generation organoid technologies and translational pharmacology, offering protocols and scientific rationale for integrating this peptide in hiPSC-derived systems. In contrast to prior work linking Gastrin I (human) to organoid workflows (see here), which surveys the peptide’s general role in advanced models, we uniquely emphasize the harmonization of CCK2 receptor signaling studies with pharmacokinetic and disease modeling within human-specific platforms.

Advanced Applications in Gastrointestinal Disorder Research and Drug Development

Modeling Disease States and Therapeutic Mechanisms

The ability to modulate gastric acid secretion via Gastrin I (human) in hiPSC-derived organoids unlocks new avenues for GI disorder research, including:

• Modeling hypergastrinemia and related neoplastic syndromes by sustained CCK2 receptor stimulation.
• Dissecting the interplay between proton pump activation and epithelial barrier integrity in conditions such as peptic ulcer disease or H. pylori infection.
• Evaluating candidate drugs targeting CCK2 receptor pathways or H⁺/K⁺-ATPase inhibitors, advancing preclinical therapeutic screening in a human-relevant context.

Pharmacokinetic and Drug-Drug Interaction Studies

Leveraging the matured enterocyte-like cells within hiPSC-derived intestinal organoids, studies incorporating Gastrin I (human) can simulate the impact of altered gastric acidity on oral drug absorption and metabolism. This is critical for understanding drug bioavailability and drug-drug interactions, as emphasized in the reference study (Saito et al., 2025), which established IOs as versatile platforms for pharmacokinetic assessment. Here, Gastrin I (human) serves not only as a physiological modulator but as a precision tool for mechanistic dissection and translational research.

Optimizing Experimental Workflows: Best Practices and Troubleshooting

Peptide Handling and Quality Control

The high purity and stability of Gastrin I (human) (B5358) are essential for reproducible results. Researchers should avoid prolonged storage of peptide solutions and ensure complete dissolution in DMSO prior to dilution into culture media. Batch-to-batch consistency, confirmed by rigorous HPLC and mass spectrometry, is vital for quantifiable and interpretable outcomes in organoid-based assays.

Assay Design: Dose Response and Receptor Specificity

Experimental protocols should incorporate titration of Gastrin I (human) to define concentration-dependent effects on CCK2 receptor signaling and downstream proton pump activity. Parallel assays with receptor antagonists or gene-silencing approaches can validate specificity and distinguish direct from off-target effects. This granularity is critical for establishing causal relationships in complex organoid systems.

Conclusion and Future Outlook

The integration of Gastrin I (human) into hiPSC-derived intestinal organoid platforms heralds a new era for gastric acid secretion pathway research, gastrointestinal physiology studies, and translational GI disorder research. Unlike prior reviews that focus broadly on organoid modeling or the peptide’s basic utility, our analysis underscores the synergy between advanced human-specific models and the precise biochemical properties of Gastrin I (human) as a CCK2 receptor agonist. This approach enables highly controlled, physiologically relevant experiments that bridge fundamental discovery with clinical application—a leap forward from traditional methodologies and previously published perspectives.

As organoid technology continues to evolve, the use of rigorously characterized reagents like Gastrin I (human) will be indispensable for unraveling complex GI pathologies, optimizing drug development pipelines, and personalizing therapeutic interventions. For deeper insight into experimental protocols and troubleshooting strategies, complementary perspectives can be found in this recent article, which offers additional workflow optimizations. Together, these resources position Gastrin I (human) as an essential tool for the next generation of GI research.